Previous 10 | Next 10 |
Synlogic (NASDAQ: SYBX ) -25% in reaction to its decision to terminate development of SYNB1020 for the treatment of hyperammonemia. More news on: Synlogic, Inc., Sarepta Therapeutics, Inc., Fabrinet, Stocks on the move, Read more ...
BOULDER, Colo., Aug. 15, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, announced today that William S. Marshall, Ph.D., President and Chief Exec...
BOULDER, Colo., Aug. 12, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, announced today that William S. Marshall, Ph.D., President and Chief Exec...
miRagen Therapeutics, Inc. (MGEN) Q2 2019 Earnings Conference Call August 7, 2019 4:30 PM ET Company Participants Dan Ferry – Managing Director-LifeSci Advisors, LLC Bill Marshall – President and Chief Executive Officer Jason Leverone – Chief Financial Office...
Miragen Therapeutics (NASDAQ: MGEN ): Q2 GAAP EPS of -$0.29 beats by $0.07 . More news on: Miragen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
miRagen to regain global rights to MRG-110 after Servier provides notice of portfolio realignment; expects to announce Phase 1 data during the second half of 2019 Company anticipates reporting primary endpoint data from the SOLAR clinical trial in the first half of 2021 Restructurin...
Thinly traded nano cap Miragen Therapeutics ( MGEN -19.8% ) slumps on almost triple normal volume ahead of its Q2 results to be released after the close tomorrow. More news on: Miragen Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Gainers: EverQuote (NASDAQ: EVER ) +47% . NeoPhotonics Corporation (NYSE: NPTN ) +27% . Invacare Corporation (NYSE: IVC ) +23% . Adient plc (NYSE: ADNT ) +23% . Ducommun Incorporated (NYSE: DCO ) +22% . Insulet Corporation (NASDAQ: PODD ) +19% . Greenlight Capital Re (NASDAQ: G...
BOULDER, Colo., July 24, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will host a conference call on Wednesday, August 7 th , at 4:30 p.m. ET t...
Gainers: Immuron (NASDAQ: IMRN ) +81% . Blue Apron Holdings (NYSE: APRN ) +49% . Moxian (NASDAQ: MOXC ) +35% . GAIN Capital Holdings (NYSE: GCAP ) +32% . Lonestar Resources (NASDAQ: LONE ) +19% . AVROBIO (NASDAQ: AVRO ) +17% . Dolphin Entertainment (NASDAQ: DLPN ) +16% . Bio-P...
News, Short Squeeze, Breakout and More Instantly...
Miragen Therapeutics Inc. Company Name:
MGEN Stock Symbol:
NASDAQ Market:
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRD...
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance mult...